258 related articles for article (PubMed ID: 25267440)
1. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma.
Berkowitz JL; Janik JE; Stewart DM; Jaffe ES; Stetler-Stevenson M; Shih JH; Fleisher TA; Turner M; Urquhart NE; Wharfe GH; Figg WD; Peer CJ; Goldman CK; Waldmann TA; Morris JC
Clin Immunol; 2014 Dec; 155(2):176-87. PubMed ID: 25267440
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Chen J; Zhang M; Ju W; Waldmann TA
Blood; 2009 Feb; 113(6):1287-93. PubMed ID: 18948574
[TBL] [Abstract][Full Text] [Related]
3. CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation.
Locke FL; Pidala J; Storer B; Martin PJ; Pulsipher MA; Chauncey TR; Jacobsen N; Kröger N; Walker I; Light S; Shaw BE; Beato F; Laport GG; Nademanee A; Keating A; Socie G; Anasetti C
Biol Blood Marrow Transplant; 2017 Mar; 23(3):405-411. PubMed ID: 28007665
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 receptor targeted therapy of ocular disease of HTLV-1-associated adult T-cell leukemia.
Larson TA; Hu M; Janik JE; Nussenblatt RB; Morris JC; Sen HN
Ocul Immunol Inflamm; 2012 Aug; 20(4):312-4. PubMed ID: 22642512
[TBL] [Abstract][Full Text] [Related]
5. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Waldmann TA
J Clin Immunol; 2007 Jan; 27(1):1-18. PubMed ID: 17216565
[TBL] [Abstract][Full Text] [Related]
6. Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25.
Zhang Z; Zhang M; Garmestani K; Talanov VS; Plascjak PS; Beck B; Goldman C; Brechbiel MW; Waldmann TA
Blood; 2006 Aug; 108(3):1007-12. PubMed ID: 16569769
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients.
Jacobs JF; Punt CJ; Lesterhuis WJ; Sutmuller RP; Brouwer HM; Scharenborg NM; Klasen IS; Hilbrands LB; Figdor CG; de Vries IJ; Adema GJ
Clin Cancer Res; 2010 Oct; 16(20):5067-78. PubMed ID: 20736326
[TBL] [Abstract][Full Text] [Related]
8. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Osherov M; Milo R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
[TBL] [Abstract][Full Text] [Related]
9. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma.
Waldmann TA
Oncogene; 2007 May; 26(25):3699-703. PubMed ID: 17530023
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability.
Pise-Masison CA; Radonovich M; Dohoney K; Morris JC; O'Mahony D; Lee MJ; Trepel J; Waldmann TA; Janik JE; Brady JN
Blood; 2009 Apr; 113(17):4016-26. PubMed ID: 19131553
[TBL] [Abstract][Full Text] [Related]
11. Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL).
Ceesay MM; Matutes E; Taylor GP; Fields P; Cavenagh J; Simpson S; Ho A; Devereux S; Mufti GJ; Pagliuca A
Leuk Res; 2012 Jul; 36(7):857-61. PubMed ID: 22209076
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on anti-CD25: daclizumab in MS.
Schippling DS; Martin R
Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab for the treatment of multiple sclerosis.
Papadopoulou A; Derfuss T; Sprenger T
Neurodegener Dis Manag; 2017 Oct; 7(5):279-297. PubMed ID: 28849702
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
15. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis.
Martin R
Neurodegener Dis; 2008; 5(1):23-6. PubMed ID: 18075271
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study.
Gold R; Radue EW; Giovannoni G; Selmaj K; Havrdova E; Stefoski D; Sprenger T; Montalban X; Cohan S; Umans K; Greenberg SJ; Ozen G; Elkins J
BMC Neurol; 2016 Jul; 16():117. PubMed ID: 27461166
[TBL] [Abstract][Full Text] [Related]
17. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.
Bielekova B; Howard T; Packer AN; Richert N; Blevins G; Ohayon J; Waldmann TA; McFarland HF; Martin R
Arch Neurol; 2009 Apr; 66(4):483-9. PubMed ID: 19364933
[TBL] [Abstract][Full Text] [Related]
18. 90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphoma.
Janik JE; Morris JC; O'Mahony D; Pittaluga S; Jaffe ES; Redon CE; Bonner WM; Brechbiel MW; Paik CH; Whatley M; Chen C; Lee JH; Fleisher TA; Brown M; White JD; Stewart DM; Fioravanti S; Lee CC; Goldman CK; Bryant BR; Junghans RP; Carrasquillo JA; Worthy T; Corcoran E; Conlon KC; Waldmann TA
Proc Natl Acad Sci U S A; 2015 Oct; 112(42):13045-50. PubMed ID: 26438866
[TBL] [Abstract][Full Text] [Related]
19. Mogamulizumab for the treatment of relapsed or refractory adult T-cell leukemia-lymphoma.
Winsett FT; Lewis DJ; Duvic M
Expert Rev Hematol; 2017 Sep; 10(9):757-760. PubMed ID: 28756726
[TBL] [Abstract][Full Text] [Related]
20. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Diao L; Hang Y; Othman AA; Nestorov I; Tran JQ
Clin Pharmacokinet; 2016 Aug; 55(8):943-55. PubMed ID: 26873229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
